# MAZE — Maze Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** MAZE  
**Sources:** 16  
**Published:** 2026-10-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-maze-maze-therapeutics-inc-catalysts-narrative-risks-9805

---

# Maze Therapeutics, Inc. (Nasdaq: MAZE) — As of 2026-10-28

## Recent catalysts (last ~1–3 months)

**Q2 2026 financials and pipeline update (Aug 11, 2026).** The company reported $494.9 million in cash, cash equivalents, and marketable securities, with a cash runway into 2029, and reported $20.0 million in license revenue (a milestone under the exclusive Shionogi license for MZE001) against a Q2 net loss of $44.7 million ($0.76/share) and R&D expenses of $34.9 million [[8]](https://finance.yahoo.com/healthcare/articles/maze-therapeutics-reports-second-quarter-200100991.html)[[9]](https://finance.yahoo.com/healthcare/articles/maze-therapeutics-reports-second-quarter-200100991.html). Management reaffirmed Phase 2 HORIZON enrollment for MZE829 is on track and that the Phase 2 CIPheR trial for MZE782 in PKU has been initiated, with topline data expected in 2027 and a MZE782 CKD trial targeted for H1 2027 [[7]](https://biotechreporter.news/maze-therapeutics-nasdaqmaze-reports-second-quarter-2026-financial-results-and-pipeline-updates/)[[8]](https://finance.yahoo.com/healthcare/articles/maze-therapeutics-reports-second-quarter-200100991.html).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-maze-maze-therapeutics-inc-catalysts-narrative-risks-9805 (free to sign up)._